Navigation Links
UCF professor develops vaccine to protect against black plague bioterror attack
Date:11/13/2008

A University of Central Florida researcher may have found a defense against the Black Plague, a disease that wiped out a third of Europe's population in the Middle Ages and which government agencies perceive as a terrorist threat today.

UCF Professor Henry Daniell and his team have developed a vaccine that early research shows is highly effective against the plague. Findings of his National Institutes of Health and USDA funded research appear in the August edition of Infection and Immunity. The vaccine, which is taken orally or by injection, was given to rats at UCF and the efficacy was evaluated by measuring immunity (antibody) developed in their blood.

All untreated rats died within three days while all orally immunized animals survived this challenge with no traces of the plague in their bodies. The rats were exposed to a heavy dose of Yersinia Pestis bacteria, which causes the plague, at the U.S. Army Medical Research Institute of Infectious Diseases in Maryland. It is one of a few labs in the world authorized to store and work with the highly dangerous agent.

"We are very excited because it appears the oral vaccine is even more effective than traditional injectable vaccine," Daniell said. "This could really make a difference."

In the event of a bioterror attack, the oral form makes the vaccine practical, as the distribution of pills would be much quicker and likely more effective because no special skills or sterile needles are needed to administer them.

"It worked beautifully," Daniell said. "It's expensive to create an injectible vaccine. But with oral vaccines, it is quite cheap. You grow your plants and then you convert them into capsules."

The plague had a deadly impact on early Europe, it continues to make appearances today in places like Africa and Asia. The World Health Organization reports at least 2,000 cases of the plague annually. The most recent outbreak in 2005 killed 56 people in the Congo and another 124 were infected before the epidemic was stopped. In the mid 1990s more than 400 people were infected in India.

Although human trials are still needed, Daniell is confident the vaccine will work for the bubonic and pneumonic plague based on animal studies. Pneumonic plague is spread through the air. Without treatment a person can die within days. Bubonic plague is the more common form and is transmitted through fleabites and kills about 70 percent of those infected within 4-7 days if not treated. It was the version that ravaged Europe. If the early findings hold true, this vaccine could mean an extra layer of protection against natural epidemics and man-made threats.

The Centers for Disease Control lists the pneumonic plague as a potential bioterrorism agent because of the speed of which it can be spread and its 60 percent fatality rate if not treated early enough with an aggressive array of antibiotics.

Daniell was inspired to investigate an oral vaccine for the plague because of his pioneering work in diabetes. He and his team genetically engineered tobacco and lettuce plants with the insulin gene and then administered freeze-dried plant cells to five-week-old diabetic mice for eight weeks. By the end of this study, the diabetic mice had normal blood and urine sugar levels, and their cells were producing normal levels of insulin.

Daniell figured the same approach might work with a vaccine. He genetically engineered plant cells with a protein found on the outside of Yersinia pestis. The vaccine was inside the plant cells, which were given to the rats. The vaccine was protected from digestion in the stomach and was then absorbed in the gut. It kick started the immune system into producing antibodies, which protects against the deadly disease. Three to five doses seem to do the trick.

Daniell, who was born and raised in India, has dedicated his life to finding treatments and cures to diseases that ravage poor countries. He is conducting research into seven of the top 10 diseases ranked by the World Health Organization and the Centers for Disease Control, which remain real issues developing nations.

"I've seen the need. There may be some very expensive treatments available," Daniell said. "But they are so expensive that developing countries can't access them. I want to help change that."


'/>"/>

Contact: Zenaida Gonzalez Kotala
zkotala@mail.ucf.edu
407-446-6567
University of Central Florida
Source:Eurekalert

Related biology technology :

1. Yale professor T.P. Ma awarded the Connecticut Medal of Technology
2. Stuart Parkin first distinguished professor at Eindhoven University of Technology
3. UCF professor develops vaccine to protect against black plague bioterror attack
4. Professor-turned-producer learns the movie biz
5. Professors Marc Feldmann and Sir Ravinder Maini Named Winners of the 2008 Dr. Paul Janssen Award for Biomedical Research
6. Professor Toh-Ming Lu named fellow of the Materials Research Society
7. Professor Straufs research is Nature Photonics’ cover article
8. Cambridge Major Appoints Professor John Hartwig as Scientific Advisor
9. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
10. Dr. Thomas Van Dyke Renowned Boston University Professor Joins Imagenetixs Medical Advisory Board
11. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... CA (PRWEB) , ... October ... ... a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today ... of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration ...
(Date:10/10/2017)... ... ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. ... event entitled “Stem Cells and Their Regenerative Powers,” was held on August 31st, ... was joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic Surgery, ...
(Date:10/10/2017)... 10, 2017 SomaGenics announced the receipt of ... develop RealSeq®-SC (Single Cell), expected to be the first ... (including microRNAs) from single cells using NGS methods. The ... to accelerate development of approaches to analyze the heterogeneity ... "New techniques for measuring levels of mRNAs in individual ...
(Date:10/10/2017)... PITTSBURGH, PA (PRWEB) , ... October 10, 2017 ... ... this year’s recipients of 13 prestigious awards honoring scientists who ... be presented in a scheduled symposium during Pittcon 2018, the world’s leading conference ...
Breaking Biology Technology:
(Date:3/30/2017)... , March 30, 2017 The research ... system for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D ... a new realm of speed and accuracy for use in identification, ... an affordable cost. ... ...
(Date:3/28/2017)... PUNE, India , March 28, 2017 ... (Analog, IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), ... Maintenance), Vertical, and Region - Global Forecast to 2022", ... 30.37 Billion in 2016 and is projected to reach ... 15.4% between 2017 and 2022. The base year considered ...
(Date:3/24/2017)... 2017 Research and Markets has announced the ... & Trends - Industry Forecast to 2025" report to their ... The Global ... CAGR of around 15.1% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
Breaking Biology News(10 mins):